Prothena Corp. Plc (PRTA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Prothena Corp. Plc (PRTA)
Go deeper and ask any question about PRTA
Company Performance
Current Price
as of Sep 13, 2024$22.11
P/E Ratio
N/A
Market Cap
$1.19B
Description
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Metrics
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryBiotechnology
- TickerPRTA
- Price$22.11+6.71%
Trading Information
- Market Cap$1.19B
- Float86.32%
- Average Daily Volume (1m)256,141
- Average Daily Volume (3m)428,615
- EPS-$0.95
Company
- Revenue$217.25M
- Rev Growth (1yr)3,184.75%
- Net Income$66.89M
- Gross Margin99.32%
- EBITDA Margin44.90%
- EBITDA$59.27M
- EV$584.08M
- EV/Revenue2.69
- P/EN/A
- P/S5.60
Documents
SEC Filings
Factset Street Account
Analysts debate Prothena read-across from Leqembi subcutaneous update at CTAD (2023-10-26T14:02:55Z)
Factset